智通财经APP获悉，三生制药(01530)涨超8%，截至发稿，涨8.22%，报9.22港元，成交额3.99亿港元。
消息面上，三生制药此前公布，近期于JPM大会上披露的II期临床阶段性分析数据显示，707在非小细胞肺癌（NSCLC）和转移性结直肠癌（mCRC）患者的治疗上展现出优异的客观缓解率（ORR）和疾病控制率（DCR），尤其在NSCLC适应症上，无论单药还是与化疗联用，707均展示了显著的抗肿瘤活性和良好的安全性。据东吴证券预计，SSGJ-707国内销售峰值约40亿元，海外（欧美）销售峰值有望达到45亿美金。
东吴证券研报指出，公司核心产品特比澳、促红素及蔓迪等贡献80多亿收入、20多亿利润，对应7倍PE，估计每年拥有近5-10%增长，近60亿现金资产全面支持创新药研发，年研发投入近10亿处于行业前列；多年创新药不仅孵化三生国健优质自免创新药平台，更培育出或合作开发 SSGJ707、自免系列产品及口服紫杉醇等，尤其 SSGJ707在J.P.M展示积极II数据，有BEST-IN-CLASS全球竞争力，海外BD预期为股价提供较大弹性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.